Zoetis Inc. $ZTS Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 95.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 18,655 shares of the company’s stock after selling 416,742 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Zoetis were worth $1,341,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP grew its position in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. State Street Corp grew its position in Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after purchasing an additional 149,382 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after purchasing an additional 189,235 shares during the period. Finally, Norges Bank acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $734,425,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 2.9%

Shares of NYSE:ZTS opened at $73.64 on Friday. The company has a 50 day moving average of $76.30 and a 200-day moving average of $99.01. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market cap of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74. Zoetis Inc. has a twelve month low of $71.45 and a twelve month high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the business earned $1.76 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ZTS. TD Cowen reduced their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. William Blair reaffirmed a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Barclays cut their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.